NDimension was established by Roger Mason, the managing director, in 2014 to provide an expanding range of advanced electrophysiological assays and bespoke engineering/instrumentation solutions to the biopharmaceutical industries and academia. Contributing to drug discovery, neurotech development and pure research, model assays are currently offered in the fields of neuro- and sensory-degeneration, neuropsychiatry, neurodevelopmental disorders, pain and epilepsy, for projects in regenerative medicine, pre-clinical compound development, neurotoxicity and seizurogenic screening.